News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Myriad Genetics, Inc. Reports First Quarter Fiscal 2010 Financial Results
November 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SALT LAKE CITY, Nov. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its fiscal first quarter ended September 30, 2009.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Immunology and inflammation
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
September 17, 2026
·
1 min read
·
Tristan Manalac
Layoff Tracker
Sionna says good-bye to 46% of staffers, including exec
September 16, 2026
·
93 min read
·
BioSpace Editorial Staff
Funding
Sling catches $123M series C for thyroid eye disease pill
September 16, 2026
·
2 min read
·
Tristan Manalac
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
